본문 바로가기
KERD
논문KCI 등재

Chronic Hepatitis C

Raymond T. Chung|장재영
거트앤리버 소화기연관학회협의회|2011.06|Gut and Liver|제5권 제2호|pp. 117-132

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

TherapeuticsChronic hepatitis CVirology

초록

The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment. Major improvements in antiviral therapy for chronic hepatitis C have occurred in the past decade. The addition of ribavirin to interferon-alfa therapy and the introduction of pegylated interferon (PEG-IFN) have substantially improved SVR rates in patients with chronic hepatitis C. The optimization of HCV therapy with PEG-IFN and ribavirin continues to evolve. Studies are ongoing that use viral kinetics to tailor therapy to an individual’s antiviral response and determine the ideal length of treatment to maximize the chance of SVR. Improved SVR can be achieved with new specifi c inhibitors that target the HCV NS3/4A protease and the NS5B polymerase. Several long-term follow-up studies have shown that SVR, when achieved, is associated with a very low risk of virologic relapse. Furthermore, antiviral therapy can reduce the morbidity and mortality rates associated with chronic hepatitis C by reducing fi brosis progression, the incidence of cirrhosis, and hepatocellular carcinoma.

Abstract

The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment. Major improvements in antiviral therapy for chronic hepatitis C have occurred in the past decade. The addition of ribavirin to interferon-alfa therapy and the introduction of pegylated interferon (PEG-IFN) have substantially improved SVR rates in patients with chronic hepatitis C. The optimization of HCV therapy with PEG-IFN and ribavirin continues to evolve. Studies are ongoing that use viral kinetics to tailor therapy to an individual’s antiviral response and determine the ideal length of treatment to maximize the chance of SVR. Improved SVR can be achieved with new specifi c inhibitors that target the HCV NS3/4A protease and the NS5B polymerase. Several long-term follow-up studies have shown that SVR, when achieved, is associated with a very low risk of virologic relapse. Furthermore, antiviral therapy can reduce the morbidity and mortality rates associated with chronic hepatitis C by reducing fi brosis progression, the incidence of cirrhosis, and hepatocellular carcinoma.

참고문헌 (149)

  1. Alter MJ, "The prevalence of hepatitis C virus infection in the United States, 1988 through 1994", N Engl J Med, 341, pp.556~562 (1999)
  2. Liang TJ, "Pathogenesis, natural history, treatment, and prevention of hepatitis C", Ann Intern Med, 132, pp.296~305 (2000)
  3. Cerny A, "Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence", Hepatology, 30, pp.595~601 (1999)
  4. Davis GL, "Combination treatment with interferon and ribavirin for chronic hepatitis C", Clin Liver Dis, 3, pp.811~826 (1999)
  5. Centers for Disease Control and Prevention, "Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease", MMWR Recomm Rep, 47(RR- 19), pp.1~39 (1998)
  6. Alter MJ, "Epidemiology of hepatitis C virus infection", World J Gastroenterol, 13, pp.2436~2441 (2007)
  7. Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
  8. Garten RJ, "Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China", Int J Epidemiol, 33, pp.182~188 (2004)
  9. Higuchi M, "Epidemiology and clinical aspects on hepatitis C", Jpn J Infect Dis, 55, pp.69~77 (2002)
  10. Yoshizawa H, "Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future", Oncology, 62(Suppl 1), pp.8~17 (2002)
  11. Iino S, "Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan", Antivir Ther, 3(Suppl 3), pp.143~146 (1998)
  12. Fishman SL, "The quasispecies nature and biological implications of the hepatitis C virus", Infect Genet Evol, 9, pp.1158~1167 (2009)
  13. Mondelli MU, "Clinical significance of hepatitis C virus genotypes", J Hepatol, 31(Suppl 1), pp.65~70 (1999)
  14. Global surveillance and control of hepatitis C, "Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
  15. Nguyen MH, "Chronic hepatitis C: genotypes 4 to 9", Clin Liver Dis, 9, pp.411~426 (2005)
  16. Kamal SM, "Hepatitis C genotype 4: what we know and what we don’t yet know", Hepatology, 47, pp.1371~1383 (2008)
  17. Choo QL, "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome", Science, 244, pp.359~362 (1989)
  18. Poynard T, "Viral hepatitis C", Lancet, 362, pp.2095~2100 (2003)
  19. Ji H, "Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA", Proc Natl Acad Sci U S A, 101, pp.16990~16995 (2004)
  20. Griffin S, "Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes", J Virol, 79, pp.15525~15536 (2005)
  21. Kato N, "Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer", Hepatology, 32, pp.405~412 (2000)
  22. Ray RB, "Suppression of apoptotic cell death by hepatitis C virus core protein", Virology, 226, pp.176~182 (1996)
  23. Zhu N, "Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis", J Virol, 72, pp.3691~3697 (1998)
  24. Hosui A, "Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli", J Biol Chem, 273, pp.28562~28571 (2003)
  25. Miller K, "Effects of the hepatitis C virus core protein on innate cellular defense pathways", J Interferon Cytokine Res, 24, pp.391~402 (2004)
  26. Shimotohno K, "Hepatitis C virus and its roles in cell proliferation", J Gastroenterol, 37(Suppl 13), pp.50~54 (2002)
  27. Kamegaya Y, "Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis", Hepatology, 41, pp.660~667 (2005)
  28. Moriya K, "Hepatitis C virus core protein induces hepatic steatosis in transgenic mice", J Gen Virol, 78(Pt 7), pp.1527~1531 (1997)
  29. Abrignani S, "Perspectives for a hepatitis C virus vaccine", Clin Diagn Virol, 10, pp.181~185 (1998)
  30. Qiao M, "Hepatitis C virus- like particles combined with novel adjuvant systems enhance virus-specific immune responses", Hepatology, 37, pp.52~59 (2003)
  31. Baumert TF, "Hepatitis C virus structural proteins assemble into viruslike particles in insect cells", J Virol, 72, pp.3827~3836 (1998)
  32. Lechmann M, "Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice", Hepatology, 34, pp.417~423 (2001)
  33. Taylor DR, "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein", Science, 285, pp.107~110 (1999)
  34. Sakai A, "The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences", Proc Natl Acad Sci U S A, 100, pp.11646~11651 (2003)
  35. Franck N, "Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome", J Virol, 79, pp.2700~2708 (2005)
  36. Prikhod’ko EA, "The NS3 protein of hepatitis C virus induces caspase- 8-mediated apoptosis independent of its protease or helicase activities", Virology, 329, pp.53~67 (2004)
  37. Breiman A, "Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon", J Virol, 79, pp.3969~3978 (2005)
  38. Loo YM, "Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection", Proc Natl Acad Sci U S A, 103, pp.6001~6006 (2006)
  39. Tellinghuisen TL, "The NS5A protein of hepatitis C virus is a zinc metalloprotein", J Biol Chem, 279, pp.48576~48587 (2004)
  40. Brass V, "An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A", J Biol Chem, 277, pp.8130~8139 (2002)
  41. Moradpour D, "Function follows form: the structure of the N-terminal domain of HCV NS5A", Hepatology, 42, pp.732~735 (2005)
  42. Tanji Y, "Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A", J Virol, 69, pp.3980~3986 (1995)
  43. Reed KE, "Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase", J Virol, 71, pp.7187~7197 (1997)
  44. Ide Y, "Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase Aalpha catalytic subunit", Gene, 201, pp.151~158 (1997)
  45. Appel N, "Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain", J Virol, 79, pp.3187~3194 (2005)
  46. Huang Y, "Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade", Hepatology, 43, pp.81~90 (2006)
  47. Macdonald A, "Hepatitis C virus NS5A: tales of a promiscuous protein", J Gen Virol, 85(Pt 9), pp.2485~2502 (2004)
  48. Penin F, "Structural biology of hepatitis C virus", Hepatology, 39, pp.5~19 (2004)
  49. Lesburg CA, "Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site", Nat Struct Biol, 6, pp.937~943 (1999)
  50. Biswal BK, "Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors", J Biol Chem, 820, pp.18202~18210 (2005)
  51. Domitrovich AM, "Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication", Virology, 335, pp.72~86 (2005)
  52. Luo G, "De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus", J Virol, 74, pp.851~863 (2000)
  53. Ishii N, "Diverse effects of cyclosporine on hepatitis C virus strain replication", J Virol, 80, pp.4510~4520 (2006)
  54. Pileri P, "Binding of hepatitis C virus to CD81", Science, 282, pp.938~941 (1998)
  55. Flint M, "The role of the hepatitis C virus glycoproteins in infection", Rev Med Virol, 10, pp.101~117 (2000)
  56. Meola A, "Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection", J Virol, 74, pp.5933~5938 (2000)
  57. Masciopinto F, "Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection", Virology, 304, pp.187~196 (2002)
  58. Cormier EG, "CD81 is an entry coreceptor for hepatitis C virus", Proc Natl Acad Sci U S A, 101, pp.7270~7274 (2004)
  59. Flint M, "Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein", J Virol, 73, pp.6782~6790 (1999)
  60. Germi R, "Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption", J Med Virol, 68, pp.206~215 (2002)
  61. Bartosch B, "Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor", J Biol Chem, 278, pp.41624~41630 (2003)
  62. Evans MJ, "Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry", Nature, 446, pp.801~805 (2007)
  63. Ploss A, "Human occludin is a hepatitis C virus entry factor required for infection of mouse cells", Nature, 457, pp.882~886 (2009)
  64. Rodríguez-Iñigo E, "Histological damage in chronic hepatitis C is not related to the extent of infection in the liver", Am J Pathol, 154, pp.1877~1881 (1999)
  65. Rehermann B, "Cell mediated immune response to the hepatitis C virus", Curr Top Microbiol Immunol, 242, pp.299~325 (2000)
  66. Zhou S, "Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia", Hepatology, 24, pp.1041~1046 (1996)
  67. Puoti C, "Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels", Liver, 19, pp.104~109 (1999)
  68. Romeo R, "Lack of association between type of hepatitis C virus, serum load and severity of liver disease", J Viral Hepat, 3, pp.183~190 (1996)
  69. Bowen DG, "Adaptive immune responses in acute and chronic hepatitis C virus infection", Nature, 436, pp.946~952 (2005)
  70. Gale M Jr, "Evasion of intracellular host defence by hepatitis C virus", Nature, 436, pp.939~945 (2005)
  71. Iwasaki A, "Toll-like receptor control of the adaptive immune responses", Nat Immunol, 5, pp.987~995 (2004)
  72. Haller O, "The interferon response circuit: induction and suppression by pathogenic viruses", Virology, 344, pp.119~130 (2006)
  73. Malmgaard L, "Induction and regulation of IFNs during viral infections", J Interferon Cytokine Res, 24, pp.439~454 (2004)
  74. "Hepatology", 2006, A267~
  75. Romero-Gómez M, "Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients", Gastroenterology, 128, pp.636~641 (2005)
  76. Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.339~401 (2009)
  77. Thompson AJ, "Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus", Gastroenterology, 139, pp.120~129 (2010)
  78. Darling JM, "Optimizing treatment regimens in hepatitis C", Clin Liver Dis, 10, pp.835~850 (2006)
  79. McHutchison JG, "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection", N Engl J Med, 360, pp.1827~1838 (2009)
  80. Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
  81. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
  82. Manns MP, "Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
  83. Lindsay KL, "Introduction to therapy of hepatitis C", Hepatology, 36(5 Suppl 1), pp.S114~S120 (2002)
  84. Davis GL, "Monitoring of viral levels during therapy of hepatitis C", Hepatology, 36(5 Suppl 1), pp.S145~S151 (2002)
  85. Shiffman ML, "Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3", N Engl J Med, 357, pp.124~134 (2007)
  86. Davis GL, "Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C", Hepatology, 38, pp.645~652 (2003)
  87. Sethi A, "Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response", Clin Liver Dis, 9, pp.453~471 (2005)
  88. Jensen DM, "Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)", ribavirin therapy, 2006, pp.43, 954~960
  89. Berg T, "Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin", Gastroenterology, 130, pp.1086~1097 (2006)
  90. Sánchez-Tapias JM, "Peginterferonalfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment", Gastroenterology, 131, pp.451~460 (2006)
  91. Bronowicki JP, "Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin", Gastroenterology, 131, pp.1040~1048 (2006)
  92. Heathcote EJ, "Re-treatment of chronic hepatitis C with consensus interferon", Hepatology, 27, pp.1136~1143 (1998)
  93. Lindsay KL, "A randomized, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C", Hepatology, 34, pp.395~403 (2001)
  94. Reddy KR, "Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C", Hepatology, 33, pp.433~438 (2001)
  95. Shiffman ML, "Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha", Hepatology, 46, pp.371~379 (2007)
  96. Snoeck E, "Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin", Br J Clin Pharmacol, 62, pp.699~709 (2006)
  97. Shiffman ML, "Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C", Gastroenterology, 132, pp.103~112 (2007)
  98. McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
  99. Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  100. Swain MG, "A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin", Gastroenterology, 139, pp.1593~1601 (2010)
  101. Desmond CP, "Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting", J Viral Hepat, 13, pp.311~315 (2006)
  102. Formann E, "Long-term followup of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy", Aliment Pharmacol Ther, 23, pp.507~511 (2006)
  103. 김철현, "만성 C형간염에서 인터페론", 페그인터페론과 리바비린 병합요법 후 지속바이러스반응 유지에 대한 고찰, 2009, pp.15(1), 70~79[DOI]
  104. Maheshwari A, "Management of acute hepatitis C", Clin Liver Dis, 14, pp.169~176 (2010)
  105. Staples CT Jr, "Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival", Clin Infect Dis, 29, pp.150~154 (1999)
  106. Greub G, "Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study", Lancet, 356, pp.1800~1805 (2000)
  107. Rumi MG, "High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels", Ann Intern Med, 112, pp.379~380 (1990)
  108. Bica I, "Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection", Clin Infect Dis, 32, pp.492~497 (2001)
  109. Sherman KE, "Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group", Clin Infect Dis, 34, pp.831~837 (2002)
  110. Allory Y, "Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study", Hum Pathol, 31, pp.69~74 (2000)
  111. Chung RT, "Peginterferon Alfa- 2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons", N Engl J Med, 351, pp.451~459 (2004)
  112. Torriani FJ, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients", N Engl J Med, 351, pp.438~450 (2004)
  113. Carrat F, "Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial", JAMA, 292, pp.2839~2848 (2004)
  114. Laguno M, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV", HCV co-infected patients, 2004, pp.18, F27~F36
  115. Vento S, "Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy", AIDS, 12, pp.116~117 (1998)
  116. Rutschmann OT, "Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV", J Infect Dis, 177, pp.783~785 (1998)
  117. Niu MT, "Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members", Am J Kidney Dis, 22, pp.568~573 (1993)
  118. Fabrizi F, "Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey", Nephron, 80, pp.428~433 (1998)
  119. Sterling RK, "Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation", Am J Gastroenterol, 94, pp.3576~3582 (1999)
  120. Cotler SJ, "Characteristics of hepatitis C in renal transplant candidates", J Clin Gastroenterol, 35, pp.191~195 (2002)
  121. Stehman-Breen CO, "Risk of death among chronic dialysis patients infected with hepatitis C virus", Am J Kidney Dis, 32, pp.629~634 (1998)
  122. Nakayama E, "Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy", J Am Soc Nephrol, 11, pp.1896~1902 (2000)
  123. Mathurin P, "Impact of hepatitis B and C virus on kidney transplantation outcome", Hepatology, 29, pp.257~263 (1999)
  124. Hanafusa T, "Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy", Transplant Proc, 30, pp.122~124 (1998)
  125. Fabrizi F, "Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies", Am J Transplant, 5, pp.2433~2440 (2005)
  126. Therret E, "Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study", Transplantation, 58, pp.625~628 (1994)
  127. Magnone M, "Interferon-alpha-induced acute renal allograft rejection", Transplantation, 59, pp.1068~1070 (1995)
  128. Tokumoto T, "Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C", Transplant Proc, 30, pp.3270~3272 (1998)
  129. Russo MW, "Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety", Am J Gastroenterol, 98, pp.1610~1615 (2003)
  130. Meyers CM, "Hepatitis C and renal disease: an update", Am J Kidney Dis, 42, pp.631~657 (2003)
  131. Maylin S, "Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C", Gastroenterology, 135, pp.821~829 (2008)
  132. Marcellin P, "Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon- alpha therapy", Ann Intern Med, 127, pp.875~881 (1997)
  133. Abdelmalek MF, "Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C", Liver Transpl, 10, pp.199~207 (2004)
  134. Bruno S, "Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study", Hepatology, 51, pp.2069~2076 (2010)
  135. Veldt BJ, "Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis", Ann Intern Med, 147, pp.677~684 (2007)
  136. Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCVrelated cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
  137. Kwo P, "HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron™ (peginterferon ALFA-2B)", ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C, 2009, pp.50(Suppl 1), S4~
  138. Jang JY, "New treatments for chronic hepatitis C", Korean J Hepatol, 16, pp.263~277 (2010)
  139. Chiaramonte M, "Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis", Cancer, 85, pp.2132~2137 (1999)
  140. Simonetti RG, "Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case-control study", Ann Intern Med, 116, pp.97~102 (1992)
  141. Stroffolini T, "Characteristics of hepatocellular carcinoma in Italy", J Hepatol, 29, pp.944~952 (1998)
  142. Yu MC, "Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States", J Natl Cancer Inst, 82, pp.1038~1041 (1990)
  143. Tanaka K, "Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection", J Natl Cancer Inst, 88, pp.742~746 (1996)
  144. Fattovich G, "Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients", Gastroenterology, 112, pp.463~472 (1997)
  145. Niederau C, "Prognosis of chronic hepatitis C: results of a large, prospective cohort study", Hepatology, 28, pp.1687~1695 (1998)
  146. Degos F, "Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death", Gut, 47, pp.131~136 (2000)
  147. Sun CA, "Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan", Am J Epidemiol, 157, pp.674~682 (2003)
  148. Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
  149. [URL]

관련 논문AI추천

Optimizing the Dose and Duration of Therapy for Chronic Hepatitis CErik Groessl, Helen Yee, Nipaporn Pichetshote, Samuel B. Ho거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제1호Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin김종한, 김지현, 박성재, 설상영, 송영진, 이상헌, 이연재, 이재익, 정은욱, 지삼룡, 최병진, 최상분, 최정식대한간학회 · Clinical and Molecular Hepatology2011 · 제17권 제3호Durability of Sustained Virologic Response in Chronic Hepatitis CAhmet Danalioglu, Ahmet Uyanikoglu, Binnur Pinarbasi, Fatih Besisik, Fatih Ermis, Filiz Akyuz, Kadir Demir, Sabahattin Kaymakoglu, Yilmaz Cakaloglu거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제4호The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase InhibitorsPaul Y. Kwo, Rakesh Vinayek거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제4호Emerging Therapies for Hepatitis C김도영, 안상훈, 한광협거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제5호Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis권영오, 김경훈, 서정일, 이창형, 이헌주, 장병국, 정우진, 탁원영, 황재석대한간학회 · Clinical and Molecular Hepatology2011 · 제17권 제3호

이 간행물의 다른 논문 (21건)

Biliary Strictures after Liver TransplantationSung-Koo Lee, 류충헌pp. 133-142Pathology of Epstein-Barr Virus-Associated Gastric Carcinoma and Its Relationship to PrognosisKyoung Mee Kim, Hye-Jong Songpp. 143-148Differential LINE-1 Hypomethylation of Gastric Low-Grade Dysplasia from High Grade Dysplasia and Intramucosal Cancer이정록, 이윤경, 정성훈, 한석원, 정우철, 김진동, 이강문, 정지한, 백창렬pp. 149-153KLF4 Expression Correlates with the Degree of Differentiation in Colorectal CancerLi Zuo, Wei Wei, Ruolei Hu, Yan Zuo, Qiang Wu, Shuyu Gui, Chao Liu, Sumei Zhang, Yuan Wang, Qing Zhoupp. 154-159Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation during Endoscopic Submucosal Dissection: A Prospective, Randomized Controlled Study김영호, 이준행, 민병훈, 이풍렬, 장동경, 강기주, 임현숙, 이종철, 김재준, 김진용, 이미정pp. 160-164
원문 보기